These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 33239410

  • 1. Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD.
    Muanda FT, Weir MA, Bathini L, Clemens KK, Perkovic V, Sood MM, McArthur E, Sontrop JM, Kim RB, Garg AX.
    Clin J Am Soc Nephrol; 2020 Dec 07; 15(12):1728-1739. PubMed ID: 33239410
    [Abstract] [Full Text] [Related]

  • 2. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, Sambevski S, Bessette LG, Santiago Ortiz AJ, Kulldorff M, Schneeweiss S.
    Circulation; 2019 Jun 18; 139(25):2822-2830. PubMed ID: 30955357
    [Abstract] [Full Text] [Related]

  • 3. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N, CARMELINA Investigators.
    Circulation; 2019 Jan 15; 139(3):351-361. PubMed ID: 30586723
    [Abstract] [Full Text] [Related]

  • 4. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED, Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group.
    JAMA Cardiol; 2016 May 01; 1(2):126-35. PubMed ID: 27437883
    [Abstract] [Full Text] [Related]

  • 5. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA, McGuire DK, Pieper KS, Lokhnygina Y, Strandberg TE, Riefflin A, Delibasi T, Peterson ED, White HD, Scott R, Holman RR.
    Cardiovasc Diabetol; 2019 Sep 03; 18(1):116. PubMed ID: 31481069
    [Abstract] [Full Text] [Related]

  • 6. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 7. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG, Yoon D, Park S, Han SJ, Kim DJ, Lee KW, Park RW, Kim HJ.
    Circ Heart Fail; 2017 Sep 14; 10(9):. PubMed ID: 28899989
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, Hiyoshi T, Inoue I, Iso K, Yoshii H, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2020 Jan 07; 19(1):1. PubMed ID: 31910850
    [Abstract] [Full Text] [Related]

  • 9. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
    Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR, TECOS Study Group.
    Diabetes Care; 2016 Dec 07; 39(12):2304-2310. PubMed ID: 27742728
    [Abstract] [Full Text] [Related]

  • 10. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
    Fralick M, Colacci M, Thiruchelvam D, Gomes T, Redelmeier DA.
    Diabetes Obes Metab; 2021 Apr 07; 23(4):950-960. PubMed ID: 33336894
    [Abstract] [Full Text] [Related]

  • 11. Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease.
    Cowan A, Jeyakumar N, Kang Y, Dixon SN, Garg AX, Naylor K, Weir MA, Clemens KK.
    Clin J Am Soc Nephrol; 2022 Jun 07; 17(6):835-842. PubMed ID: 35618342
    [Abstract] [Full Text] [Related]

  • 12. Sitagliptin and heart failure hospitalization in patients with type 2 diabetes.
    Tseng CH.
    Oncotarget; 2016 Sep 20; 7(38):62687-62696. PubMed ID: 27409676
    [Abstract] [Full Text] [Related]

  • 13. Higher-Dose Gabapentinoids and the Risk of Adverse Events in Older Adults With CKD: A Population-Based Cohort Study.
    Muanda FT, Weir MA, Ahmadi F, Sontrop JM, Cowan A, Fleet JL, Blake PG, Garg AX.
    Am J Kidney Dis; 2022 Jul 20; 80(1):98-107.e1. PubMed ID: 34979160
    [Abstract] [Full Text] [Related]

  • 14. Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.
    Eurich DT, Simpson S, Senthilselvan A, Asche CV, Sandhu-Minhas JK, McAlister FA.
    BMJ; 2013 Apr 25; 346():f2267. PubMed ID: 23618722
    [Abstract] [Full Text] [Related]

  • 15. Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study.
    Hung YC, Lin CC, Huang WL, Chang MP, Chen CC.
    Sci Rep; 2016 Jul 27; 6():30499. PubMed ID: 27460913
    [Abstract] [Full Text] [Related]

  • 16. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan.
    Chang CH, Chang YC, Lin JW, Caffrey JL, Wu LC, Lai MS, Chuang LM.
    Int J Cardiol; 2016 Oct 01; 220():14-20. PubMed ID: 27389437
    [Abstract] [Full Text] [Related]

  • 17. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
    Huang H, Shetty S, Bauer E, Lang K.
    Curr Med Res Opin; 2018 Jun 01; 34(6):1021-1027. PubMed ID: 29231750
    [Abstract] [Full Text] [Related]

  • 18. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
    Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Najafzadeh M, Koeneman L, Farsani SF, Déruaz-Luyet A, Paik JM, Patorno E.
    JAMA Netw Open; 2022 Oct 03; 5(10):e2237606. PubMed ID: 36264574
    [Abstract] [Full Text] [Related]

  • 19. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Tonneijck L, Smits MM, Muskiet MH, Hoekstra T, Kramer MH, Danser AH, Ter Wee PM, Diamant M, Joles JA, van Raalte DH.
    Diabetes Care; 2016 Nov 03; 39(11):2042-2050. PubMed ID: 27585605
    [Abstract] [Full Text] [Related]

  • 20. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
    Chen DY, Wang SH, Mao CT, Tsai ML, Lin YS, Chou CC, Wen MS, Wang CC, Hsieh IC, Hung KC, Chen TH.
    Int J Cardiol; 2015 Feb 15; 181():200-6. PubMed ID: 25528312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.